Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) – Research analysts at William Blair decreased their Q2 2024 EPS estimates for shares of Allogene Therapeutics in a research report issued on Tuesday, May 14th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.39) for the quarter, down from […]